跳至主要内容
临床试验/NCT02862483
NCT02862483Unknown3 期

The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction

IlDong Pharmaceutical Co Ltd1 个研究点 分布在 1 个国家目标入组 330 人开始时间: 2016年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
入组人数
330
试验地点
1
主要终点
The change of IIEF-EF(International Index of Erectile Function sum of questions-Erectile function) domain

研究概览

简要总结

The efficacy and safety of the combination of tamsulosin and tadalafil in men with lower urinary tract symptoms due to benign prostatic hyperplasia and Erectile Dysfunction: a randomized, double blinded, parallel design, active controlled, multi-center, phase 3 clinical trial

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Male aged 45 years old or older
  • Subjects who have PSA ≤ 4.0 ng/mL Visit2
  • Subjects who have Total IPSS score ≥ 13
  • Subjects who have IIEF-EF domain ≤ 24 and each point below 3 in question 3 and 4

排除标准

  • Subjects who have hypersensitivity to investigational product or sulfa medications

研究组 & 干预措施

Experimental

Experimental

Tamsulosin 0.2mg and Tadalafil 5mg

干预措施: Tamsulosin 0.2mg (Drug)

Experimental

Experimental

Tamsulosin 0.2mg and Tadalafil 5mg

干预措施: Tadalafil 5mg (Drug)

Comparator

Active Comparator

placebo for Tamsulosin 0.2mg and Tadalafil 5mg

干预措施: Tadalafil 5mg (Drug)

Comparator

Active Comparator

placebo for Tamsulosin 0.2mg and Tadalafil 5mg

干预措施: Placebo for Tamsulosin (Drug)

结局指标

主要结局

The change of IIEF-EF(International Index of Erectile Function sum of questions-Erectile function) domain

时间窗: From baseline at week 12

The change of total IPSS(International prostate symptom score)

时间窗: From baseline at week 12

次要结局

  • The percentage of patients who have increased score about IIEF questions number 3 and 4(at least 1 point) compared to the baseline(From baseline at week 12)
  • CGIC(Clinician Global Impression of change) score(At week 12)
  • The change of IIEF(International Index of Erectile Function) score about questions number 3 and 4(From baseline at week 12)
  • The change of IPSS(International prostate symptom score) QoL(Quality of Life)(From baseline at week 4,8 and 12)
  • The change of PVR(Post Void Residual Volume)(From baseline at week 4,8 and 12)
  • The change of total IPSS(International prostate symptom score)(From baseline at week 4,8)
  • The change of total IPSS(International prostate symptom score) sub score (storage, voiding)(From baseline at week 4,8 and 12)
  • PGIC(Patient Global Impression of change) score(At week 12)
  • The change of IIEF (International Index of Erectile Function sum of questions) total score(From baseline at week 4,8 and 12)
  • The change of IIEF-IS(International Index of Erectile Function sum of questions-Intercourse satisfaction) domain score measured by IIEF question number 6~8(From baseline at week 4,8 and 12)
  • The change of OF(Orgasmic function) domain score measured by IIEF question number 9 and 10)(From baseline at week 4,8 and 12)
  • The change of IIEF-EF domain(International Index of Erectile Function sum of questions-Erectile function) score measured by IIEF question number 1~5 and 15(From baseline at week 4,8)
  • The change of Qmax(maximum urinary flow rate)(From baseline at week 4,8 and 12)
  • The change of OS(Overall satisfaction) domain score measured by IIEF question number13 and 14(From baseline at week 4,8 and 12)
  • The percentage of patients who have more than 4 point about IIEF questions number 3 and 4(From baseline at week 12)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验